Shots:

• The approval is based on two P-III study results assessing Aklief (trifarotene- qd) vs vehicle in 2-420 patients with moderate acne on the face and trunk
• The P-III studies demonstrated reduction of inflammatory lesions as early as two weeks on the face and four weeks on the back- shoulders and chest compared to vehicle with well tolerated results
• Aklief (trifarotene) Cream 0.005% is a topical treatment used for targeting retinoic acid receptor (RAR) gamma designed for of acne vulgaris in patients 9 years of age and older with its expected availability in Nov 2019

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Twitter